Clinical trial · Observational
MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are not asked to change patient care based on this information.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Solid Tumor | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Personalized Cancer Monitoring (PCM) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- Through study completion, up to 5 years
- measure
- Relapse Free Survival
- timeFrame
- Measured through study completion, assessed yearly up to 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria 1. Stated ability to give informed consent by participant. 2. Stated health status of participant as healthy enough to provide Biological Material. 3. Individuals diagnosed with solid cancer of any type, including but not limited to colorectal, non-small cell lung, breast, ovarian and bladder cancers, regardless of the length of time since diagnosis and regardless of previous therapies. 4. Participant is of any biological sex and \>18 years of age 5. Participant has not undergone a blood transfusion within the previous three weeks Exclusion Criteria 1. Participants who are deemed medically unstable 2. Participants who are deemed to be "difficult to draw" blood from. 3. Participants who are \<18 years of age 4. Participants diagnosed with CNS cancers, sarcomas or hematologic malignancies such as leukemia or lymphoma . 5. Participants with more than one primary cancer 6. Participants with FFPE slides older than 10 years 7. Participants who are pregnant 8. Any other reason that, in the Investigator's judgment, that would preclude the participant from being able to participate in the study 9. Participants for which a pathology report is not available
References
Publications (0)
Data not yet available